INTRODUCTION
including nausea, vomiting, transient hypotension, anaphylaxis, and groin hematoma 5) 23) , we focused on neurological complications secondary to thromboembolism.
Thromboembolism is the most significant complication of cerebral DSA 14) , which occurs secondary to thrombus formation within catheters, within pre-existing friable intravascular thrombotic plaques, or device-induced microdissections 11) .
Antiplatelet and anticoagulant therapy effectively reduces the risk of thromboembolism 13)18) . Several studies have reported that periprocedural antiplatelet therapy effectively lowers the incidence of thromboembolic complications (TEC) that may occur with coiling of unruptured aneurysms 15-17)24) . However, to the best of our knowledge, no studies have been performed for diagnostic cerebral DSA. We hypothesized that preprocedural administration of dual antiplatelet agents (aspirin and cilostazol) for 7 days may reduce the risk of complications associated with diagnostic cerebral DSA.
MATERIALS AND METHODS

Patients
We retrospectively reviewed the records of 419 patients who underwent diagnostic cerebral DSA between September 2015 and April 2018 (Table 1) . 
Drug Protocols
Patients who underwent DSA between July 2016
and April 2018 received aspirin and cilostazol (both 100 mg/day) for 7 days. All antiplatelet therapy was discontinued post-procedure in premedicated patients who underwent cerebral DSA but did not develop TEC.
Statistical Analysis
Comparison between two groups was performed us- 
RESULTS
We analyzed the complication ratio based on risk factors including hypertension, diabetes mellitus, hyperlipidemia, history of stroke, smoking, heart disease such as heart failure or arrhythmia, chronic kidney disease, and others that can affect the vascular status.
Our analysis showed that these risk factors did not significantly affect the incidence of DSA-induced TEC ( (1.0%) developed diplopia ( Fig. 2) and motor weakness respectively, and acute ischemic stroke was confirmed on MRI (p=0.019) ( Table 4) . Of the 13 patients diagnosed with DSA-induced TEC, 7 presented motor weakness, 4 reported visual disturbance, and 1 reported dysarthria and paresis (Table 5) . 
. Magnetic resonance image in treated premedication
Image shows a man who was premedicated with dual antiplatelet therapy and was diagnosed with an acute ischemic stroke involving the right pretectal region. He complained of a diplopia.
Fig. 1. Magnetic resonance image in untreated premedication
Diffusion-weighted magnetic resonance imaging scan obtained in a woman who developed right-sided motor weakness immediately after diagnostic cerebral digital subtraction angiography for an unruptured aneurysm. An acute ischemic stroke involving the left thalamus and both occipital lobes was confirmed as a thromboembolic complication. Of note, she had not been administered premedication. We defined cerebral DSA-induced TEC as the occurrence of acute ischemic stroke that was confirmed on MRI within 48 hours of testing in patients with neurological symptoms.
Presently, the key concern is to minimize diagnostic cerebral DSA-related complications and identify strat- , which are related to the operator's skill. Thrombus formation may occur in catheters, in pre-existing friable intravascular thrombotic plaques, or device-induced microdissections 17) .
In this study, a single neurosurgeon performed all cerebral DSA procedures, thereby minimizing the complication rate related to variations in operator's skill. However, TEC secondary to emboli originating from an existing thrombus when the device passes into the vessel cannot be avoided. We concluded that this pathomechanism of thrombus formation is a major contributor to cerebral DSA-induced ischemic stroke. Therefore, we assumed that preprocedural antiplatelet therapy could effectively reduce cerebral DSA-induced TEC. Moreover, we hypothesized that premedication using dual antiplatelet therapy could be more effective than the use of a single antiplatelet agent.
Several studies have reported that the dual antiplatelet therapy compared to single antiplatelet ther- . The effect of aspirin lasts approximately 7 to 10 days corresponding to the lifespan of platelet 7) . The premedication period was determined for 7 days in this study based on this fact. This study suggests that preprocedural dual antiplatelet therapy can significantly reduce the cerebral DSA-induced TEC rate. However, there are some limitations on this study. First, considering the effect of learning curve of operator is the limitation of this paper, further reevaluation will be needed in the future.
Second, although our population is the perfect representation of our center, we could not determine whether this population was representative of the entirety of population who were performed cerebral DSA. Third, this study was retrospective and consisted only of the available data at a single institution.
A better designed randomized controlled trial would be needed.
CONCLUSIONS
The use of dual antiplatelet agents (aspirin and cilostazol) over a week before the procedure may reduce the risks of cerebral DSA-induced complications.
